Join to View Full Profile
35 Park StNew Haven, CT 06519
Phone+1 203-200-4363
Fax+1 203-200-6385
Dr. Bewersdorf is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterResidency, Internal Medicine, 2018 - 2021
Ludwig Maximilian University of Munich Faculty of MedicineClass of 2017
Certifications & Licensure
CT State Medical License 2018 - 2026
NY State Medical License 2022 - 2024
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective Study.Cassandre Petit, Jules Higue, Ziyad Acheaibi, Julia Gilhodes, Marie-Anne Hospital
American Journal of Hematology. 2025-05-01 - Imetelstat in myeloid malignancies: current data and future directions.Aram Bidikian, Jan P Bewersdorf, Tariq Kewan, Nikolai A Podoltsev, Maximilian Stahl
Expert Review of Anticancer Therapy. 2025-03-28 - Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment.Abdulrahman Alhajahjeh, Maximilian Stahl, Tae K Kim, Tariq Kewan, Jessica M Stempel
Expert Review of Anticancer Therapy. 2025-03-27
Abstracts/Posters
- Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...Jan Philipp Bewersdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Populati...Jan Philipp Bewersdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceJan Philipp Bewersdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
